Publique en esta revista
Información de la revista
Vol. 2. Núm. 5.
Páginas 247-250 (Septiembre - Octubre 2006)
Vol. 2. Núm. 5.
Páginas 247-250 (Septiembre - Octubre 2006)
Originales
Acceso a texto completo
Micofenolato de mofetilo en nefritis lúpica refractaria a ciclofosfamida intravenosa
Mycophenolate mofetil in lupus nephritis refractory to intravenous cyclophosphamide
Visitas
...
Leonel Dazaa,
Autor para correspondencia
leonel.daza@imss.gob.mx
daza6208@hotmail.com

Correspondencia: Dr. L. Daza. Unidad de Investigación Clínica. Unidad Médica de Alta Especialidad IMSS Blvd. A. López Mateos e Insurgentes, s/n. Colonia, Moderna. 37480 León Guanajuato. México.
, Salvador Pérezb, Ulises Velascob, Martha Hernándeza
a Unidad de Investigación Clínica. Unidad Médica de Alta Especialidad IMSS. León Guanajuato. México
b Departamento de Reumatología. Unidad Médica de Alta Especialidad IMSS. León Guanajuato. México
Información del artículo
Objetivo

Evaluar el uso del micofenolato de mofetilo (MMF) en pacientes con nefropatía lúpica (NL) y fracaso al tratamiento inicial con ciclofosfamida intravenosa (i.v.), durante un período de 12 meses.

Pacientes y métodos

Se incluyeron 11 pacientes con NL. La dosis de MMF fue de 1,5-2 g/día. Se midieron la depuración de creatinina, creatinina sérica y proteinuria en orina de 24 h; asimismo, se anotaron los episodios adversos con el tratamiento durante los 12 meses.

Resultados

La proteinuria basal disminuyó con MMF de 1,63 (intervalo de confianza [IC] del 95%, 0,78-2,5) a 0,93 g/l (IC del 95%, 0,1-1,62) en el doceavo mes, con un valor de p = 0,04. La depuración de creatinina tuvo una tendencia a la mejoría, sin embargo no hubo diferencia estadística, 69,2 (IC del 95%, 51,4-87,4) frente a 79,29 ml/min (IC del 95%, 49,2-109,3), con una p = 0,90. Las demás variables no mostraron diferencias significativas. Los pacientes que no respondieron a MMF tuvieron los índices de cronicidad más altos que los pacientes con respuesta buena o regular.

Conclusión

El MMF a dosis de 1,5-2,0 g/día es una buena alternativa en la NL con bajos índices de cronicidad y con fallo a la ciclofosfamida i.v., sin efectos colaterales graves.

Palabras clave:
Nefritis lúpica
Micofenolato mofetilo
Ciclofosfamida
Lupus eritematoso generalizado
Objective

To evaluate the use of mycophenolate mofetil (MMF) in lupus nephritis (LN) patients with prior failure to intravenous cyclophosphamide over a 12-month follow-up.

Patients and methods

Eleven patients with LN were included. MMF doses ranged from 1.5-2 grams per day. In all patients, 24-h urinary protein excretion, creatinine clearance, and serum creatinine were evaluated. Treatment-related adverse effects were recorded over the 12-month follow-up.

Results

Basal proteinuria decreased from 1.63 g/L (95% CI: 0.78-2.5) to 0.93 (95% CI: 0.1-1.62) g/L at the end of the follow-up period (p = 0.04). Creatinine clearance showed a tendency to improve but no statistically significant differences were found, 69.2 (95% CI 51.4- 87.4) vs. 79.29 (IC 95% 49.2-109.3) ml/min, respectively; p = 0.90). No significant differences were found in the remaining variables. Patients without response to MMF had a higher chronicity index than those with good or average response.

Conclusion

MMF doses of 1.5-2 grams per day are a good alternative in LN patients without response to intravenous cyclophosphamide and a low chronicity index. No severe adverse effects were found.

Key words:
Lupus nephritis
Mycophenolate mofetil
Cyclophosphamide
Systemic lupus erythematosus
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.C. Carrol.
The lupus paradox: Natural immunity is protective against disease.
Kidney Int, 65 (2004), pp. 1540
[2.]
D. Pisetski.
Systemic lupus erythematosus, epidemiology, pathology and pathogenesis.
Primer on the rheumatic diseases, pp. 246-251
[3.]
L. Martins, G. Rocha, A. Rodríguez, J. Santos, C. Vasconcelos, J. Correia, et al.
Lupus nephritis: a retrospective review of 78 cases from a single center.
Clin Nephrol, 57 (2002), pp. 114-119
[4.]
S.M. Korbet, E.J. Lewis, M.M. Schwartz, M. Reichlin, J. Evans, R.D. Rohde.
Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group.
Am J Kidney Dis, 35 (2000), pp. 904-914
[5.]
R. Cervera, M. Khamashta, J. Font, G. Sebastián, A. Gil, P. Lavilla, The European Working Party on Systemic Lupus Erythematosus, et al.
Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients.
Medicine, 72 (1993), pp. 113-124
[6.]
M. Abu Shakra, M. Urowitz, D. Gladman, J. Gough.
Mortality studies in systemic lupus erythematosus results from a single center. I. Causes of death.
J Rheumatol, 22 (1995), pp. 1259-1264
[7.]
R. Herrera-Esparza, O. Barbosa, H. Villalobos, E. Avalos.
Renal expression of IL-6 and TNF alpha genes in lupus nephritis.
Lupus, 7 (1998), pp. 134-138
[8.]
I. Badillo-Almaraz, L. Daza, E. Avalos-Díaz, R. Herrera-Esparza.
Glomerular expression of FAS ligand and BAX mRNA in lupus nephritis.
Autoimmunity, 34 (2001), pp. 283-289
[9.]
H.A. Austin III, J.H. Klippel, J.E. Balow, N.G. Le Riche, A.D. Steinberg, P.H. Plotz, et al.
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
N Engl J Med, 314 (1986), pp. 614-619
[10.]
M.F. Gourley, I.II. Austin HA, D. Scott, C.H. Yarboro, E.M. Vaughan, J. Muir, et al.
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.
Ann Intern Med, 125 (1996), pp. 549-557
[11.]
R.E. Bullingham, A.J. Nicholls, B.R. Kamm.
Clinical pharmacokinetics of mycophenolate mofetil.
Clin Pharmacokinetics, 34 (1998), pp. 429
[12.]
A.C. Allison, E.M. Eugui.
Mycophenolate mofetil and its mechanisms of action.
Immunopharmacology, 47 (2000), pp. 85
[13.]
C.A. Jonsson, H. Carlsten.
Mycophenolic acid inhibits inosine 5’-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages.
Cell Immunol, 216 (2002), pp. 93-101
[14.]
G. Contreras, V. Pardo, B. Leclercq, O. Leonz, E. Tozman, P. O’Nan, et al.
Sequential therapies for proliferative lupus nephritis.
N Engl J Med, 350 (2004), pp. 971-980
[15.]
J. Cross, A. Dwomoa, P. Andrews, A. Burns, C. Gordon, J. Main, Renal Association Clinical Trials Subcommittee, et al.
Mycophenolate mofetil for remission induction in severe lupus nephritis.
Nephron Clin Pract, 100 (2005), pp. c92-c100
[16.]
E.M. Tan, A.S. Cohen, J.F. Fries, A.T. Masi, D.J. McShane, N.F. Rothfield, et al.
The 1982 revised criteria for the classification of systemic lupus erythematosus.
Arthritis Rheum, 25 (1982), pp. 1271-1277
[17.]
E.M. Ginzler, C. Aranow.
Mycophenolate mofetil in lupus nephritis.
Lupus, 14 (2005), pp. 59-64
[18.]
G. Hill, M. Delahousse, D. Nochy, C.H. Mandet, J. Bariéty.
Proteinuria and tubulointerstitial lesions in lupus nephritis.
Kidney Int, 60 (2001), pp. 1893-1903
[19.]
J.P. Grande, J.E. Balow.
Renal biopsy in lupus nephritis.
Lupus, 7 (1998), pp. 611-617
[20.]
S. Bujais, J. Ordi-Ros, J. Paredes, M. Mauri, L. Matas, J. Cortés, et al.
Contribution of the inicial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients.
Ann Rheum Dis, 62 (2003), pp. 859-865
[21.]
L. Ding, M. Zhao, W. Zou, Y. Liu, H. Wang.
Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study.
Lupus, 13 (2004), pp. 113-118
[22.]
T.M. Chan, K.C. Tse, C.S. Tang, M.Y. Mok, F.K. Li.
Long-term study of mycophenolate mofetil as continous induction and maintenance treatment for diffuse proliferative lupus nephritis.
J Am Soc Nephrol, 16 (2005), pp. 1076-1084
Copyright © 2006. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?